Hyloris Pharmaceuticals's quarterly market cap
declined
from Dec. 2024 (€189.84 Mil) to Jun. 2025 (€176.40 Mil) but then
increased
from Jun. 2025 (€176.40 Mil) to Dec. 2025 (€191.52 Mil).
Hyloris Pharmaceuticals's annual market cap
declined
from Dec. 2023 (€356.98 Mil) to Dec. 2024 (€189.84 Mil) but then
increased
from Dec. 2024 (€189.84 Mil) to Dec. 2025 (€191.52 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hyloris Pharmaceuticals's Enterprise Value for Today is €114.40 Mil.
Hyloris Pharmaceuticals (LTS:0AB6) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Hyloris Pharmaceuticals Market Cap Related Terms
Hyloris Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0AB6 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Hyloris Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Hyloris Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals (LTS:0AB6) has a Market Cap of €126.56 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hyloris Pharmaceuticals and its competitors. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #675 out of 1427 companies in the Biotechnology industry, placing it in the top 47.3%.
Is Hyloris Pharmaceuticals' Market Cap too high?
Hyloris Pharmaceuticals' current Market Cap is €126.56 Mil. Based on the distribution chart, Hyloris Pharmaceuticals ranks #675 out of 1427 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Hyloris Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #675 out of 1427 companies for Market Cap. This puts Hyloris Pharmaceuticals in the upper half of its industry. The industry median Market Cap is 119.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hyloris Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyloris Pharmaceuticals's current Market Cap is €126.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.52, compared to a current price of €4.64 — trading 51.3% below its estimated fair value. The current Market Cap is €126.56 Mil. Hyloris Pharmaceuticals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Market Cap is €126.56 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.64 is trading 51.3% below its estimated GF Value™ of €9.52.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LTS:0AB6:
Market Cap: €126.56 Mil
GF Value™: €9.52 vs. price of €4.64 (51.3% below fair value)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
63GF Score
Get the complete analysis for LTS:0AB6
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
